Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH

B. H. Chung, C. G. Roehrborn, P. Siami, K. Major-Walker, B. B. Morrill, T. H. Wilson, F. Montorsi

Research output: Contribution to journalArticle

Abstract

Although ethnicity-based differences in prostate size and physiology have been reported, results of benign prostatic hyperplasia (BPH) treatment trials in predominantly Caucasian patients are assumed to be applicable to non-Caucasian populations. This post hoc analysis investigated whether an Asian subpopulation of men with moderate-to-severe BPH in the CombAT study achieves treatment responses in line with those of the overall study population. In this double-blind, randomized, parallel-group trial, 325 Asian men were assigned to treatment with 0.5mg dutasteride once daily, 0.4mg tamsulosin once daily or the combination. Decrease in international prostate symptom score (IPSS) at month 24 from baseline (the primary endpoint) was significantly greater with combination treatment compared with tamsulosin (P

Original languageEnglish
Pages (from-to)152-159
Number of pages8
JournalProstate Cancer and Prostatic Diseases
Volume12
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

tamsulosin
Prostatic Hyperplasia
Safety
Prostate
Therapeutics
Population
Dutasteride

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study : 2-year results in Asian men with moderate-to-severe BPH. / Chung, B. H.; Roehrborn, C. G.; Siami, P.; Major-Walker, K.; Morrill, B. B.; Wilson, T. H.; Montorsi, F.

In: Prostate Cancer and Prostatic Diseases, Vol. 12, No. 2, 2009, p. 152-159.

Research output: Contribution to journalArticle

@article{354623c0041b454bb9c58c337192bd8a,
title = "Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH",
abstract = "Although ethnicity-based differences in prostate size and physiology have been reported, results of benign prostatic hyperplasia (BPH) treatment trials in predominantly Caucasian patients are assumed to be applicable to non-Caucasian populations. This post hoc analysis investigated whether an Asian subpopulation of men with moderate-to-severe BPH in the CombAT study achieves treatment responses in line with those of the overall study population. In this double-blind, randomized, parallel-group trial, 325 Asian men were assigned to treatment with 0.5mg dutasteride once daily, 0.4mg tamsulosin once daily or the combination. Decrease in international prostate symptom score (IPSS) at month 24 from baseline (the primary endpoint) was significantly greater with combination treatment compared with tamsulosin (P",
author = "Chung, {B. H.} and Roehrborn, {C. G.} and P. Siami and K. Major-Walker and Morrill, {B. B.} and Wilson, {T. H.} and F. Montorsi",
year = "2009",
doi = "10.1038/pcan.2008.49",
language = "English",
volume = "12",
pages = "152--159",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study

T2 - 2-year results in Asian men with moderate-to-severe BPH

AU - Chung, B. H.

AU - Roehrborn, C. G.

AU - Siami, P.

AU - Major-Walker, K.

AU - Morrill, B. B.

AU - Wilson, T. H.

AU - Montorsi, F.

PY - 2009

Y1 - 2009

N2 - Although ethnicity-based differences in prostate size and physiology have been reported, results of benign prostatic hyperplasia (BPH) treatment trials in predominantly Caucasian patients are assumed to be applicable to non-Caucasian populations. This post hoc analysis investigated whether an Asian subpopulation of men with moderate-to-severe BPH in the CombAT study achieves treatment responses in line with those of the overall study population. In this double-blind, randomized, parallel-group trial, 325 Asian men were assigned to treatment with 0.5mg dutasteride once daily, 0.4mg tamsulosin once daily or the combination. Decrease in international prostate symptom score (IPSS) at month 24 from baseline (the primary endpoint) was significantly greater with combination treatment compared with tamsulosin (P

AB - Although ethnicity-based differences in prostate size and physiology have been reported, results of benign prostatic hyperplasia (BPH) treatment trials in predominantly Caucasian patients are assumed to be applicable to non-Caucasian populations. This post hoc analysis investigated whether an Asian subpopulation of men with moderate-to-severe BPH in the CombAT study achieves treatment responses in line with those of the overall study population. In this double-blind, randomized, parallel-group trial, 325 Asian men were assigned to treatment with 0.5mg dutasteride once daily, 0.4mg tamsulosin once daily or the combination. Decrease in international prostate symptom score (IPSS) at month 24 from baseline (the primary endpoint) was significantly greater with combination treatment compared with tamsulosin (P

UR - http://www.scopus.com/inward/record.url?scp=67349091472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349091472&partnerID=8YFLogxK

U2 - 10.1038/pcan.2008.49

DO - 10.1038/pcan.2008.49

M3 - Article

C2 - 18813219

AN - SCOPUS:67349091472

VL - 12

SP - 152

EP - 159

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 2

ER -